Healey JH, Lane JM. Chordoma: a critical review of diagnosisand treatment. Orthop Clin North Am 1989;20(3):417-26.
McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma:incidence and survival patterns in the United States,1973-1995. Cancer Causes Control 2001;12(1):1-11.
Sciubba DM, Chi JH, Rhines LD, et al. Chordoma of thespinal column. Neurosurg Clin N Am 2008;19(1):5-15.
Wold LE, Laws ER, Jr. Cranial chordomas in children andyoung adults. J Neurosurg 1983;59(6):1043-7.
Llauger J, Palmer J, Amores S, et al. Primary tumors of thesacrum: diagnostic imaging. AJR Am J Roentgenol2000;174(2):417-24.
Cheng EY, Ozerdemoglu RA, Transfeldt EE, et al. Lumbosacralchordoma. Prognostic factors and treatment. Spine (Phila Pa1976) 1999;24(16):1639-45.
Ailon T, Torabi R, Fisher CG, et al. Management of LocallyRecurrent Chordoma of the Mobile Spine and Sacrum: ASystematic Review. Spine (Phila Pa 1976) 2016;41 Suppl20:S193-S8.
Fourney DR, Gokaslan ZL. Current management of sacralchordoma. Neurosurg Focus 2003;15(2):E9.
Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factorsin chordoma of the sacrum and mobile spine: a study of 39patients. Cancer 2000;88(9):2122-34.
Bjornsson J, Wold LE, Ebersold MJ, et al. Chordoma of themobile spine. A clinicopathologic analysis of 40 patients.Cancer 1993;71(3):735-40.
Chambers PW, Schwinn CP. Chordoma. A clinicopathologicstudy of metastasis. Am J Clin Pathol 1979;72(5):765-76.
Horten BC, Montague SR. In vitro characteristics of asacrococcygeal chordoma maintained in tissue and organculture systems. Acta Neuropathol 1976;35(1):13-25.
Crapanzano JP, Ali SZ, Ginsberg MS, et al. Chordoma: acytologic study with histologic and radiologic correlation.Cancer 2001;93(1):40-51.
Holland PW, Koschorz B, Holland LZ, et al. Conservation ofBrachyury (T) genes in amphioxus and vertebrates:developmental and evolutionary implications. Development1995;121(12):4283-91.
Yang XR, Ng D, Alcorta DA, et al. T (brachyury) geneduplication confers major susceptibility to familial chordoma.Nat Genet 2009;41(11):1176-8.
Nibu Y, Jose-Edwards DS, Di Gregorio A. From notochordformation to hereditary chordoma: the many roles of Brachyury.Biomed Res Int 2013;2013:826435.
Presneau N, Shalaby A, Ye H, et al. Role of the transcriptionfactor T (brachyury) in the pathogenesis of sporadicchordoma: a genetic and functional-based study. J Pathol2011;223(3):327-35.
Li M, Zhai Y, Bai J, et al. SNF5 as a prognostic factor in skullbase chordoma. J Neurooncol 2018;137(1):139-46.
Zhai Y, Bai J, Wang S, et al. Analysis of clinical factors andPDGFR-beta in predicting prognosis of patients with clivalchordoma. J Neurosurg 2018:1-9.
Freeman JL, DeMonte F, Al-Holou W, et al. Impact of earlyaccess to multidisciplinary care on treatment outcomes inpatients with skull base chordoma. Acta Neurochir (Wien)2018;160(4):731-40.
Pallini R, Maira G, Pierconti F, et al. Chordoma of the skullbase: predictors of tumor recurrence. J Neurosurg2003;98(4):812-22.
Catton C, O’Sullivan B, Bell R, et al. Chordoma: long-termfollow-up after radical photon irradiation. Radiother Oncol1996;41(1):67-72.
Boriani S, Chevalley F, Weinstein JN, et al. Chordoma of thespine above the sacrum. Treatment and outcome in 21 cases.Spine (Phila Pa 1976) 1996;21(13):1569-77.
York JE, Kaczaraj A, Abi-Said D, et al. Sacral chordoma:40-year experience at a major cancer center. Neurosurgery1999;44(1):74-9; discussion 9-80.
Stener B, Gunterberg B. High amputation of the sacrum forextirpation of tumors. Principles and technique. Spine (PhilaPa 1976) 1978;3(4):351-66.
Hsieh PC, Xu R, Sciubba DM, et al. Long-term clinicaloutcomes following en bloc resections for sacral chordomasand chondrosarcomas: a series of twenty consecutive patients.Spine (Phila Pa 1976) 2009;34(20):2233-9.
Tzortzidis F, Elahi F, Wright D, et al. Patient outcome atlong-term follow-up after aggressive microsurgical resectionof cranial base chordomas. Neurosurgery 2006;59(2):230-7;discussion -7.
Fuchs B, Dickey ID, Yaszemski MJ, et al. Operativemanagement of sacral chordoma. J Bone Joint Surg Am2005;87(10):2211-6.
Samson IR, Springfield DS, Suit HD, et al. Operative treatmentof sacrococcygeal chordoma. A review of twenty-one cases.J Bone Joint Surg Am 1993;75(10):1476-84.
Stacchiotti S, Gronchi A, Fossati P, et al. Best practices forthe management of local-regional recurrent chordoma: aposition paper by the Chordoma Global Consensus Group.Ann Oncol 2017;28(6):1230-42.
Austin-Seymour M, Munzenrider JE, Goitein M, et al.Progress in low-LET heavy particle therapy: intracranial andparacranial tumors and uveal melanomas. Radiat Res Suppl1985;8:S219-26.
Suit HD, Goitein M, Munzenrider J, et al. Definitive radiationtherapy for chordoma and chondrosarcoma of base of skulland cervical spine. J Neurosurg 1982;56(3):377-85.
Austin-Seymour M, Munzenrider J, Linggood R, et al.Fractionated proton radiation therapy of cranial and intracranialtumors. Am J Clin Oncol 1990;13(4):327-30.
Imai R, Kamada T, Tsuji H, et al. Carbon ion radiotherapy forunresectable sacral chordomas. Clin Cancer Res2004;10(17):5741-6.
Nishida Y, Kamada T, Imai R, et al. Clinical outcome of sacralchordoma with carbon ion radiotherapy compared withsurgery. Int J Radiat Oncol Biol Phys 2011;79(1):110-6.
Schneider C, Vyfhuis M, Morse E, et al. Dramatic Responseof a Large Sacral Chordoma to Intensity Modulated ProtonBeam Therapy. Cureus 2017;9(9):e1670.
Durante M, Loeffler JS. Charged particles in radiation oncology.Nat Rev Clin Oncol 2010;7(1):37-43.
Negri T, Casieri P, Miselli F, et al. Evidence for PDGFRA,PDGFRB and KIT deregulation in an NSCLC patient. Br JCancer 2007;96(1):180-1.
Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylatein chordoma. Cancer 2004;101(9):2086-97.
Stacchiotti S, Marrari A, Tamborini E, et al. Response toimatinib plus sirolimus in advanced chordoma. Ann Oncol2009;20(11):1886-94.
Rinner B, Froehlich EV, Buerger K, et al. Establishment anddetailed functional and molecular genetic characterisation ofa novel sacral chordoma cell line, MUG-Chor1. Int J Oncol2012;40(2):443-51.
Magnaghi P, Salom B, Cozzi L, et al. Afatinib Is a NewTherapeutic Approach in Chordoma with a Unique Ability toTarget EGFR
